Advancing Trial Design: Delighted to be the #ASCO24 discussant of Biologically Driven Trial Design abstracts

Interesting poster from Yoshie Umemura w Ivy Brain Tumor Center on EGFR altered gliomas. Huge need for this population! #btsm #asco24 #clinicaltrials

Illuminating glioma evolution through spatiotemporal sampling and CSF ctDNA analyses #asco24

Advancing clinical trials: ST101 targeting C/EBPBeta, switching M2 to M1 macrophages achieves tumor penetration and increases lymphocyte and macrophage infiltration #ASCO24

GBM AGILE leadership gathering at #ASCO24 Trial leadership joined together to plan new trial innovations, advance exciting new therapies, and celebrate five years of our commitment to patients by making clinical research more efficient. Since launching in 2019, six

Niraparib best in class #PARPi PK and PD properties, moving to phase III evaluation Nader Sanai #ASCO24

Impressive advantage of PCV over TMZ in oligodendroglioma presented by ⁦⁦Mehdi Touat⁩ #asco24

Great discussion about mIDH gliomas. We 👏🏻 must 👏🏻 start 👏🏻 profiling 👏🏻 these 👏🏻. tumors!! ❓ If we don't look, we will never know. Or (as I tell my pts...) 🐟 You cannot catch a fish if you don't go fishing!! 🐠 #btsm #asco24 #IDH

IDH inhibitors but also other targeted therapies are sneaking their way into the mainstream of glioma treatment #ASCO24 Martin van den Bent Dr. Schreck

Looking forward to enrolling patients on the Gliofocus trial Nader Sanai Yoshie Umemura

Q&A: The MOAB Trial – Now Enrolling at Duke but soon at multiple other centers throughout the US. Click to learn more about this biologically driven neoadjuvant trial that will prospectively analyze on-treatment resected tumors! tischbraintumorcenter.duke.edu/blog/qa-moab-t…

Happy to share results from a new Phase 0 trial led by Ivy Brain Tumor Center Nader Sanai Shwetal Mehta, Ph.D. (she/her) and Kevin Johnson: Single nucleus transcriptomics, PK/PD of combined CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma medrxiv.org/content/10.110…

Great program and speakers Pam Rosato - fantastic organizers Katayoun Ayasoufi & Co Matt Waitkus

Evolocumab as an immunomodulator in glioma: A window of opportunity trial evaluating PCSK9 inhibition to enhance surface MHC-I on tumor medrxiv.org/content/10.110… Kirit Singh

Mustafa Khasraw 1/ Excited to share our pre-print describing our window of opportunity surgical trial in patients with glioma! We recently published on the need for more tissue-based trials to translate pre-clinical findings to human biology: nature.com/articles/s4159…

PETITION TO NEVER EVER HAVE A WORLD CUP AT A PLACE LIKE QATAR EVER AGAIN

Indeed Martin van den Bent is now a Knight of the Order of the Lion of the Netherlands - thanks Marjolein Geurts and Matthias_Preusser for the invitation to witness this

Great to have you Jonathan Kipnis 💔

Exclusive: Duke spinout launches in hopes of prevailing with brain cancer bispecific where Amgen, Roche did not - endpts.com/exclusive-duke…

I’m an immigrant, and I’ve never eaten anyone’s pet!